Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

Cancer Immunology, Immunotherapy

Volumn 65, Issue 3, 2016, Pages 327-339

  Bol, Kalijn F ^a,b   Aarntzen, Erik H J G ^a,b   Pots, Jeanette M ^a   Olde Nordkamp, Michel A M ^a   van de Rakt, Mandy W M M ^a   Scharenborg, Nicole M ^a   de Boer, Annemiek J ^a   van Oorschot, Tom G M ^a   Croockewit, Sandra A J ^b   Blokx, Willeke A M ^b   Oyen, Wim J G ^b   Boerman, Otto C ^b   Mus, Roel D M ^b   van Rossum, Michelle M ^b   van der Graaf, Chantal A A ^b   Punt, Cornelis J A ^c   Adema, Gosse J ^a   Figdor, Carl G ^a   de Vries, I Jolanda M ^a,b   Schreibelt, Gerty ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cells; Immunotherapy; Maturation; Melanoma; Prophylactic vaccines; Toll like receptor ligands

Indexed keywords

DENDRITIC CELL VACCINE; GLYCOPROTEIN GP 100; KEYHOLE LIMPET HEMOCYANIN; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR 1; TUMOR ANTIGEN; BCG VACCINE; CANCER VACCINE; HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN; MELANOCYTE PROTEIN PMEL 17;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER STAGING; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG DOSE ESCALATION; DRUG INTOXICATION; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; INJECTION SITE REACTION; INTRADERMAL DRUG ADMINISTRATION; INTRANODAL DRUG ADMINISTRATION; LIVER TOXICITY; LYMPHADENITIS; LYMPHADENOPATHY; MALE; MELANOMA; MONOCYTE; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; SKIN TEST; STEROID THERAPY; T LYMPHOCYTE; TREATMENT RESPONSE; CYTOLOGY; DENDRITIC CELL; GENETICS; IMMUNOLOGY; MIDDLE AGED; VACCINATION;

ADULT; AGED; BCG VACCINE; CANCER VACCINES; DENDRITIC CELLS; DINOPROSTONE; FEMALE; GP100 MELANOMA ANTIGEN; HEMOCYANIN; HUMANS; MALE; MELANOMA; MIDDLE AGED; MONOCYTES; MONOPHENOL MONOOXYGENASE; T-LYMPHOCYTES; VACCINATION;

EID: 84959544986     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1796-7     Document Type: Article

References (35)

1. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252
2. Figdor CG, de Vries IJM, Lesterhuis WJ, Melief CJM (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10:475–480
3. Lesterhuis WJ, Aarntzen EHJG, Vries IJM et al (2008) Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 66:118–134
4. de Vries IJM, Lesterhuis WJ, Scharenborg NM et al (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9:5091–5100
5. de Vries IJM, Krooshoop DJEB, Scharenborg NM et al (2003) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63:12–17
6. Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243–251
7. Okada H, Kalinski P, Ueda R et al (2011) Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330–336
8. Sporri R, Sousa CRE (2005) Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4(+) T cell populations lacking helper function. Nat Immunol 6:163–170
9. Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4:499–511
10. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995
11. Schreibelt G, Benitez-Ribas D, Schuurhuis D et al (2010) Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood 116:564–574
12. Berger TG, Strasser E, Smith R et al (2005) Efficient elutriation of monocytes within a closed system (Elutra (TM)) for clinical-scale generation of dendritic cells. J Immunol Methods 298:61–72
13. Aarntzen EH, Schreibelt G, Bol K et al (2012) Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 18:5460–5470
14. de Vries IJM, Lesterhuis WJ, Barentsz JO et al (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23:1407–1413
15. Aarntzen EH, De Vries IJ, Goertz JH et al (2012) Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunol Immunother 61:2003–2011
16. Aarntzen EH, Bol K, Schreibelt G et al (2012) Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res 72:6102–6110
17. de Vries IJM, Bernsen MR, Lesterhuis WJ et al (2005) Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23:5779–5787
18. Bol KF, Figdor CG, Aarntzen EHJG et al (2015) Intranodal vaccination with mRNA-optimised dendritic cells in metastatic melanoma patients. Oncoimmunology 4:e1019197
19. Van Nuffel AM, Tuyaerts S, Benteyn D et al (2012) Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods 377:23–36
20. Jacobs JF, Aarntzen EH, Sibelt LA et al (2009) Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunol Immunother 58:145–151
21. Teulings HE, Limpens J, Jansen SN et al (2015) Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 33:773–781
22. Aarntzen EH, de Vries I, Lesterhuis WJ et al (2013) Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 73:19–29
23. Lesterhuis WJ, de Vries I, Schreibelt G et al (2010) Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res 30:5091–5097
24. Wilgenhof S, Van Nuffel AM, Corthals J et al (2011) Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 34:448–456
25. Nestle FO, Alijagic S, Gilliet M et al (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4:328–332
26. Lesterhuis WJ, Schreibelt G, Scharenborg NM et al (2011) Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother 60:249–260
27. Steg A, Leleu C, Debre B, Boccon-Gibod L, Sicard D (1989) Systemic bacillus Calmette-Guerin infection, ‘BCGitis’, in patients treated by intravesical bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol 16:161–164
28. Al-Hajoj S, Memish Z, Abuljadayel N, AlHakeem R, AlRabiah F, Varghese B (2014) Molecular confirmation of Bacillus Calmette Guerin vaccine related adverse events among Saudi Arabian children. PLoS ONE 9:e113472
29. Vermorken JB, Claessen AM, van Tinteren H et al (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353:345–350
30. Aarntzen EH, Srinivas M, Bonetto F et al (2013) Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res 19:1525–1533
31. Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188:21–28
32. Bol K, Aarntzen EHJG, Hout FEM et al (2015) Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology. doi:10.1080/2162402X.2015.1057673
33. Gajewski TF (2007) Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 13:5256–5261
34. Schadendorf D, Ugurel S, Schuler-Thurner B et al (2006) Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 17:563–570
35. Lesterhuis WJ, de Vries I, Schreibelt G et al (2011) Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 17:5725–5735